Virax Biolabs' CEO James Foster Provides Shareholder Update Following Fiscal 2026 Annual Report and Fosun Diagnostics Commercial Supply Agreement
Rhea-AI Summary
Virax Biolabs (NASDAQ: VRAX) issued a shareholder update from CEO James Foster following its fiscal 2026 Annual Report and recent developments. As of March 31, 2026, Virax reported cash of $6.4 million, total assets of $8.3 million, total liabilities of $1.0 million and shareholders' equity attributable to ordinary shareholders of $7.3 million. Subsequent to year-end, the company generated approximately $3.3 million in gross proceeds from the exercise of preferred investment options, which it said strengthens liquidity and supports ViraxImmune and ImmuneSelect initiatives.
Virax highlighted a multi-country commercial supply agreement with Fosun Diagnostics to supply ImmuneSelect immune profiling products across six Southeast Asian markets, initially for tuberculosis-related research in Thailand. For fiscal 2026, research and development expenses rose to $3.7 million from $2.0 million, while general and administrative expenses fell to $2.7 million from $4.0 million and net loss narrowed to $5.0 million from $6.1 million. Following a 1-for-25 share consolidation, Nasdaq confirmed Virax regained compliance with the minimum bid price requirement. According to management, at a July 14, 2026 closing price of $3.74, Virax’s public valuation was below its audited cash balance and shareholders' equity, which management believes does not fully reflect its financial position, programs and commercial progress.
Positive
- Cash $6.4m vs liabilities $1.0m as of March 31, 2026
- $3.3m gross proceeds from preferred investment option exercise post year-end
- Net loss reduced to $5.0m from $6.1m year over year
- General and administrative expenses decreased to $2.7m from $4.0m
- R&D investment increased to $3.7m, supporting ViraxImmune and ImmuneSelect
- Nasdaq minimum bid price compliance regained after 1-for-25 share consolidation
- Multi-country ImmuneSelect supply agreement with Fosun Diagnostics in six Southeast Asian markets
Negative
- Fiscal 2026 net loss remains $5.0m despite year-over-year improvement
- Research and development expenses increased to $3.7m from $2.0m
- Management acknowledges revenue generation execution "must improve" for ImmuneSelect and ViraxImmune
- Company notes public market valuation below audited cash and shareholders' equity at $3.74 share price
News Explained
Announced on
Market reaction after fiscal 2026 annual report update: VRAX +13.04% in the Jul 16 session
In the Jul 16 session, VRAX gained 13.04%, reflecting a significant positive market reaction. Argus tracked a peak move of +29.7% during that session. Our momentum scanner triggered 51 alerts that day, indicating high trading interest and price volatility. Trading volume was very high at 3.2x the daily average, suggesting strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 09 | Financing agreement | Positive | +100.0% | Exercise of preferred investment options raising $3.3M in gross proceeds. |
| Jul 09 | Commercial supply deal | Positive | +100.0% | Exclusive multi-country ImmuneSelect supply agreement with Fosun Diagnostics. |
| Jun 24 | Share consolidation | Neutral | -14.8% | 1-for-25 share consolidation to help regain Nasdaq bid-price compliance. |
| May 26 | Clinical data update | Positive | -18.2% | Positive early ViraxImmune pilot data in Long COVID and related syndromes. |
| Apr 14 | Strategy update | Positive | -11.1% | CEO letter outlining ViraxImmune strategy and expected cash versus market cap. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent Virax headlines have produced sharp but mixed reactions, with financing and commercial deals rallying while clinical and strategic updates often coincided with declines.
Key Terms
research-use-only technical
ruo technical
nasdaq marketplace rule 5550(a)(2) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Fiscal 2026 Annual Report, filed July 2, 2026, reflects cash of
$6.4 million $8.3 million $7.3 million - Fosun Diagnostics agreement, announced July 9, 2026, supports commercial execution for ImmuneSelect across six Southeast Asian markets
- Preferred investment option exercise, completed July 10, 2026, generated approximately
$3.3 million - Nasdaq confirmed on July 13, 2026, that the Company regained compliance with the minimum bid price requirement
The Annual Report provides audited financial statements for fiscal year 2026, updates shareholders on the Company's strategic focus, and reflects the Company's recently completed 1-for-25 share consolidation. The full Annual Report is available on the
Highlights:
- Audited balance sheet position: As of March 31, 2026, Virax reported cash of
$6.4 million $8.3 million $1.0 million $6.8 million $0.7 million - Subsequent financing update: Subsequent to fiscal year end, the Company completed the exercise of preferred investment options for gross proceeds of approximately
$3.3 million - Commercial progress: Subsequent to fiscal year end, Virax announced a multi-country commercial supply agreement with Fosun Diagnostics for ImmuneSelect across six Southeast Asian markets, supporting near-term commercial supply, evaluation activity and potential regional expansion.
- Disciplined investment: Research and development expenses increased to
$3.7 million $2.0 million $2.7 million $4.0 million $5.0 million $6.1 million - Nasdaq compliance: Following the Company's 1-for-25 share consolidation, Nasdaq confirmed that Virax had regained compliance with the minimum bid price requirement under Nasdaq Marketplace Rule 5550(a)(2).
- Valuation backdrop: Based on the closing price of
$3.74
"Filing the 20-F gives investors a clearer view of Virax's audited financial position," said James Foster, Chairman and Chief Executive Officer of Virax Biolabs. "In our view, the subsequent financing, restoration of Nasdaq compliance and recent commercial progress with ImmuneSelect leave the Company better positioned to pursue near-term commercial opportunities while continuing the longer-term clinical and regulatory development of ViraxImmune™."
The full text of Mr. Foster's July 2026 shareholder update is reproduced below.
Dear Fellow Shareholders,
Following several significant developments in recent weeks, I wanted to provide shareholders with a concise update on Virax's current position and priorities.
Our fiscal 2026 Annual Report provides audited visibility into the Company's financial position. As of March 31, 2026, Virax reported cash of
Based on the July 14, 2026 closing price, the Company's public market valuation remained below its audited cash balance and shareholders' equity attributable to ordinary shareholders, notwithstanding the subsequent financing and recent commercial progress. We do not control the market and cannot predict short-term trading, but we believe this disconnect does not fully reflect the Company's cash position, modest liability profile, laboratory infrastructure, clinical and development activities, or the broader value potential of ViraxImmune™ and ImmuneSelect.
Subsequent to fiscal year end, we announced a multi-country commercial supply agreement with Fosun Diagnostics for ImmuneSelect across
Following our 1-for-25 share consolidation, Nasdaq confirmed that the Company had regained compliance with the minimum bid price requirement under Nasdaq Marketplace Rule 5550(a)(2), allowing our ordinary shares to remain listed. Maintaining Nasdaq compliance is important, but it is a foundation rather than the objective. Our focus now is execution: advancing clinical validation and evidence-generation activities for ViraxImmune™, building the U.S. market-entry pathway, translating ImmuneSelect opportunities into revenue, and communicating our progress clearly. Long-term shareholder value will ultimately depend on our ability to deliver meaningful clinical, regulatory and commercial milestones while maintaining financial discipline.
Sincerely,
James Foster
Chief Executive Officer
Virax Biolabs Group Limited
About Virax Biolabs Group Limited
Virax Biolabs Group Limited is a biotechnology company focused on immune response detection and T cell immune profiling. The Company is developing in vitro diagnostic technologies for viral and immune-mediated diseases, with an initial strategic focus on post-acute infection syndromes, including Long COVID, and related areas of chronic immune dysfunction. Its principal programs are ViraxImmune™, an in-development T cell-based immune profiling and diagnostic platform, and ImmuneSelect, a research-use-only portfolio of peptide pools, ELISpot plates and related immune reagents.
For more information, please visit www.viraxbiolabs.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial position and operating results; our business prospects and opportunities; our ability to generate revenue from ImmuneSelect or other products; our ability to advance ViraxImmune™; our ability to maintain compliance with Nasdaq listing requirements; and our clinical, regulatory and commercial plans. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms.
In evaluating these forward-looking statements, you should consider various factors, including: our ability to keep pace with new technology and changing market needs; the possibility that the commercial supply agreement with Fosun Diagnostics may not generate anticipated revenue, achieve expected commercial results, result in broader regional adoption or lead to additional purchase orders; our ability to generate revenue from ImmuneSelect or other products; our ability to maintain compliance with applicable Nasdaq listing requirements; potential for clinical trials to deliver statistically and/or clinically significant evidence of efficacy and/or safety; failure of interim or top-line results to accurately reflect the complete results of a trial; failure of planned or ongoing preclinical and clinical studies to demonstrate expected results; potential failure to continue to secure FDA and other regulators' agreement on the regulatory path for ViraxImmune™ or other potential products; and the competitive environment of our business.
These forward-looking statements are based on information currently available to Virax and its current plans or expectations and are subject to a number of known and unknown uncertainties, risks and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These and other important factors are described in detail in the "Risk Factors" section of Virax's Annual Report on Form 20-F for the year ended March 31, 2026. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions.
View original content to download multimedia:https://www.prnewswire.com/news-releases/virax-biolabs-ceo-james-foster-provides-shareholder-update-following-fiscal-2026-annual-report-and-fosun-diagnostics-commercial-supply-agreement-302827504.html
SOURCE Virax BioLabs Group Limited